Código 300410 (Harmonized System 2012 by 6 digits)
2023: US$20.8M, Total Trade Exchange
2023: US$6.73M, International Sales
2023: US$14.1M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) was US$20.8M.
In 2023, the states with the most international sales in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were Jalisco (US$3.83M), Ciudad de México (US$1.06M), and Estado de México (US$333k).
The states with the most international purchases in 2023 were Ciudad de México (US$10.2M), Jalisco (US$1.72M), and Querétaro (US$601k).
In 2023, the main commercial destinations of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were Brazil (US$1.11M), Colombia (US$876k), Panama (US$659k), Guatemala (US$578k), and Ecuador (US$516k).
The main commercial origins of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) in 2023 were Argentina (US$4.04M), France (US$3.52M), Italy (US$2.87M), United Kingdom (US$869k), and Spain (US$435k).
In the global context, the main exporting countries of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) in 2022 were India (US$513M), Austria (US$366M), and Italy (US$340M). In the same year, the main importing countries of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were United States (US$481M), Egypt (US$234M), and Germany (US$232M).
US$20.8M, Total Trade Exchange (2023)
In 2023, the total trade exchange of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) in Mexico (including international purchases and sales) was US$20.8M.
The visualizations show the net balance of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
November, 2024
In November 2024, international sales of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were US$672k, while international purchases reached US$610k. The above results in a trade balance of US$62.3k.
2024-Q4: US$756k, International Sales
The visualization shows the quarterly concentration of international sales of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) at state level.
In the fourth quarter of 2024, international sales were US$756k, being the states with the most sales Jalisco (US$702k), Ciudad de México (US$38.9k), and Estado de México (US$14.8k).
Jalisco: US$3.83M, State with the Most International Sales (2023)
Brazil: US$1.11M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were Jalisco (US$3.83M), Ciudad de México (US$1.06M), and Estado de México (US$333k).
In 2023, the countries with the most international purchases from Mexico were Brazil (US$1.11M), Colombia (US$876k), Panama (US$659k), Guatemala (US$578k), and Ecuador (US$516k).
Ciudad de México: US$10.2M, State with the Most International Purchases (2023)
Argentina: US$4.04M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were Ciudad de México (US$10.2M), Jalisco (US$1.72M), and Querétaro (US$601k).
The countries with the most international sales to Mexico in 2023 were Argentina (US$4.04M), France (US$3.52M), Italy (US$2.87M), United Kingdom (US$869k), and Spain (US$435k).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were India (US$513M), Austria (US$366M), and Italy (US$340M). In the same year, the main importing countries for Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were United States (US$481M), Egypt (US$234M), and Germany (US$232M).